New combo therapy aims to save rectums in advanced cancer patients
NCT ID NCT06864013
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment for people with locally advanced rectal cancer that has not spread. The treatment combines short-course radiation, chemotherapy, and two immunotherapy drugs (iparomlimab and tuvonralimab). The goal is to see if this approach can shrink the tumor enough to avoid surgery and preserve the rectum. About 116 adults aged 18 to 75 with a specific type of rectal cancer (MSS or pMMR) will participate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER (LARC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310006, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gut bacteria transplant help immunotherapy wipe out rectal cancer before surgery?
- New combo therapy aims to shrink rectal tumors before Surgery—Could spare some patients the knife
- New combo therapy aims to spare organs in High-Risk rectal cancer
- New drug duo takes on tough rectal cancer
- Blood test may predict rectal cancer treatment success
- New drug combo may help avoid surgery in rectal cancer patients